Katie Kosko

DocwireNews

Osimertinib (Tagrisso) can help patients with atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) live longer and with better tolerability than first-line tyrosine kinase inhibitors (TKIs), according to a recent study published in Lung Cancer.Adam Barsouk, MD, of Abramson Cancer Center and Perelman School of Medicine, and colleagues investigated osimertinib versus afatinib (Gilotrif) and erlotinib (Tarceva) outcomes in patients with atypical EGFR mutations who were treated from 2007 to 2023. The retrospective analysis evaluated progression-free survival (PFS) and overall survival (OS).&ldquo;There are limited data assessing the relative outcomes for patients with atypical EGFR mutations treated with osimertinib, afatinib, and erlotinib. These TKIs have not been compared in a head-to-head analysis of treatment outcomes for atypical EGFR mutations, leaving a key gap in the data needed to inform the management of this patient population,&rdquo; the researchers said.The analysis included 355 patients of which 90% had classical EGFR mutations that were detected on next-generation sequencing or PCR testing. Atypical EGFR mutations were seen in the remaining 10% of the population. They included the following: G719X (6%), Exon 20 (3%), L861Q (2%), S768I (1%), and C797S (0.3%). Compound mutations were discovered in 6 patients.Furthermore, baseline demographics and disease characteristics were similar among patients with classical versus atypical EGFR mutations.The researchers determined that osimertinib, a third-generation TKI, showed superior median PFS (22 months) compared with afatinib (12 months) or erlotinib (9 months).In addition, median OS was also better in patients who received osimertinib compared with the other 2 TKIs. Patients who received osimertinib saw an OS of 32 months versus 21 months with afatinib or 17 months with erlotinib.Patients were also able to tolerate osimertinib better than afatinib and erlotinib. Only 19% of patients had a dose reduction because of an adverse event (AE) with osimertinib versus 24% with afatinib or 23% with erlotinib. Discontinuation rates because of AEs were lower for osimertinib compared with afatinib or erlotinib (1% vs 2%, respectively).&ldquo;In a large real-world analysis, osimertinib demonstrated superior progression-free and overall survival and improved tolerability compared to afatinib or erlotinib for atypical EGFR-mutated mNSCLC,&rdquo; the researchers concluded.Reference<a href="https://www.lungcancerjournal.info/article/S0169-5002(24)00460-4/abstract" target="_blank" rel="noopener">Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. afatinib or erlotinib | Lung Cancer</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Real-World Analysis: Osimertinib Shows Superior Survival for Patients With Atypical EGFR-Mutated mNSCLC

Non-Small Cell Lung Cancer

Osimertinib (Tagrisso) can help patients with atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) live longer and with better tolerability than first-line TKIs. 

Osimertinib Shows Superior Survival for Patients With Atypical EGFR-Mutated mNSCLC

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe